Literature DB >> 21945861

What makes a good drug target?

Isabella Gashaw1, Peter Ellinghaus, Anette Sommer, Khusru Asadullah.   

Abstract

Novel therapeutics in areas with a high unmet medical need are based on innovative drug targets. Although 'biologicals' have enlarged the space of druggable molecules, the number of appropriate drug targets is still limited. Discovering and assessing the potential therapeutic benefit of a drug target is based not only on experimental, mechanistic and pharmacological studies but also on a theoretical molecular druggability assessment, an early evaluation of potential side effects and considerations regarding opportunities for commercialization. This article defines key properties of a good drug target from the perspective of a pharmaceutical company.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Year:  2011        PMID: 21945861     DOI: 10.1016/j.drudis.2011.09.007

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  32 in total

Review 1.  Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics.

Authors:  Tiago A Mestre; Cristina Sampaio
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

Review 2.  Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Authors:  Elaine L Shelton; Gautam K Singh; Colin G Nichols
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

3.  High-Throughput Screening Reveals New Glutaminase Inhibitor Molecules.

Authors:  Renna K E Costa; Camila T Rodrigues; Jean C H Campos; Luciana S Paradela; Marilia M Dias; Bianca Novaes da Silva; Cyro von Zuben de Valega Negrao; Kaliandra de Almeida Gonçalves; Carolline F R Ascenção; Douglas Adamoski; Gustavo Fernando Mercaldi; Alliny C S Bastos; Fernanda A H Batista; Ana Carolina Figueira; Artur T Cordeiro; Andre L B Ambrosio; Rafael V C Guido; Sandra M G Dias
Journal:  ACS Pharmacol Transl Sci       Date:  2021-12-01

Review 4.  Targeted Molecular Therapies for SBMA.

Authors:  Carlo Rinaldi; Bilal Malik; Linda Greensmith
Journal:  J Mol Neurosci       Date:  2015-11-17       Impact factor: 3.444

Review 5.  Validating therapeutic targets through human genetics.

Authors:  Robert M Plenge; Edward M Scolnick; David Altshuler
Journal:  Nat Rev Drug Discov       Date:  2013-07-19       Impact factor: 84.694

Review 6.  Targeting microRNAs for immunomodulation.

Authors:  Lukas T Jeker; Romina Marone
Journal:  Curr Opin Pharmacol       Date:  2015-05-25       Impact factor: 5.547

Review 7.  Prediction of Druggable Proteins Using Machine Learning and Systems Biology: A Mini-Review.

Authors:  Gaurav Kandoi; Marcio L Acencio; Ney Lemke
Journal:  Front Physiol       Date:  2015-12-08       Impact factor: 4.566

8.  Strategic genome-scale prioritization of unique drug targets: A case study of Streptococcus gordonii.

Authors:  Sandeep Telkar; Hulikal Shivashankara Santosh Kumar; Nagaraja Deeplanaik; Riaz Mahmood
Journal:  Bioinformation       Date:  2013-12-06

9.  Target mRNA inhibition by oligonucleotide drugs in man.

Authors:  Helen L Lightfoot; Jonathan Hall
Journal:  Nucleic Acids Res       Date:  2012-09-18       Impact factor: 16.971

10.  Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.

Authors:  Hema Dave; Miriam R Anver; Donna O Butcher; Patrick Brown; Javed Khan; Alan S Wayne; Sivasubramanian Baskar; Christoph Rader
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.